By expanding Cytovance's analytical services, we are providing sponsors with access to experienced scientists, robust analytical capabilities, and quality-driven processes...

Hear from a Cytovance expert on how perfusion is benefiting from a wave of technological advances that are making the...

By integrating perfusion into existing development platforms, Cytovance is supporting the future of biologics manufacturing technology and giving sponsors greater...

Biotech innovation is no longer concentrated in a handful of established hubs. Across the U.S., regions like Oklahoma City, Las...

In this interview with Outsourced Pharma, Anixa Biosciences's CEO, Amit Kumar, PhD, shares why Cytovance was the right CDMO partner,...

By offering in-house cell line development, Cytovance is helping clients move from concept to clinic, eliminating barriers, unlocking productivity, and...

Anixa Biosciences has selected Cytovance Biologics for Phase 2 Manufacturing of Breast Cancer Vaccine.

Cytovance recently appeared on the Outsourced Pharma Large Molecule Capabilities Update to share how our available capacity, experince in microbial...

Anixa Biosciences has selected Cytovance Biologics for Phase 2 Manufacturing of Breast Cancer Vaccine.

2026 is shaping up to be a year of steady progress for biopharmaceutical innovators. While development activity remains strong, sponsors...

Honoring its Oklahoma roots and global reach, Cytovance reflects on two decades of growth, innovation, and partnership as a trusted...

Cytovance recently appeared on the Outsourced Pharma Large Molecule Capacity Update to share how our available capacity,  current microbial and...